KalVista initiates first-in-human trial of KVD-818 for the treatment of hereditary angioedema Aug. 12, 2016 No Comments
Vonvendi launched in the U.S. as the first and only recombinant von Willebrand factor treatment Aug. 10, 2016 No Comments
Kissei and JCR initiate phase III clinical trial of the biosimilar agent JR-131 Aug. 10, 2016 No Comments
Omeros receives scientific advice from EMA on phase III program for OMS-721 July 29, 2016 No Comments
FDA grants breakthrough therapy designation to Spark Therapeutics' SPK-9001 July 22, 2016 No Comments
RSS